Tell a Friend | SmartBrief

Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.

Referral Count:

Story being shared

Stemedica licenses stem cells to Kalbe Farma

Stem Cell and Cancer Institute, a unit of PT Kalbe Farma, secured exclusive licensing rights to Stemedica Asia's ischemic-tolerant adult allogeneic mesenchymal and neural stem cells for use in clinical research in the Philippines, Thailand and Indonesia. The deal could be extended to additional countries in Asia.

Or we can send an email on your behalf

Your name(s)

Your email

Your friend's email

Message

Agree to Terms & Conditions

You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .